Kundl Facility Overview

In our new facility in Kundl, we produce proteins manufactured through mammalian cell culture technology. This includes monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), or other proteins.

Our Kundl facility is focused on improving sustainability in drug manufacturing. Through different measures, we are reducing the energy consumption and subsequent carbon footprint of this facility by approximately 50% compared to a conventional facility.

Watch the video below to learn more about the capacity of this new facility and how our highly automated cGMP capabilities can help produce your innovative therapeutic and reach patients in need.